Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Clearmind Medicine (CMND)

Clearmind Medicine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CMND
DateTimeSourceHeadlineSymbolCompany
20/06/202412:57GlobeNewswire Inc.Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD TreatmentNASDAQ:CMNDClearmind Medicine Inc
13/06/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
13/06/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
11/06/202412:44GlobeNewswire Inc.Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based DrinkNASDAQ:CMNDClearmind Medicine Inc
10/05/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
10/05/202413:24GlobeNewswire Inc.Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage ProductNASDAQ:CMNDClearmind Medicine Inc
07/05/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
07/05/202412:46GlobeNewswire Inc.Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentNASDAQ:CMNDClearmind Medicine Inc
30/04/202421:15GlobeNewswire Inc.Clearmind Applies to Cease Being a Reporting Issuer in CanadaNASDAQ:CMNDClearmind Medicine Inc
17/04/202412:49GlobeNewswire Inc.Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersNASDAQ:CMNDClearmind Medicine Inc
10/04/202412:17GlobeNewswire Inc.Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersNASDAQ:CMNDClearmind Medicine Inc
09/04/202413:07GlobeNewswire Inc.Clearmind Medicine CEO Issues Letter to ShareholdersNASDAQ:CMNDClearmind Medicine Inc
19/03/202411:55GlobeNewswire Inc.Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in ChinaNASDAQ:CMNDClearmind Medicine Inc
13/03/202412:14GlobeNewswire Inc.Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialNASDAQ:CMNDClearmind Medicine Inc
13/03/202411:30GlobeNewswire Inc.Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeNASDAQ:CMNDClearmind Medicine Inc
27/02/202412:58GlobeNewswire Inc.Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine CompoundsNASDAQ:CMNDClearmind Medicine Inc
27/02/202412:58GlobeNewswire Inc.SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine CompoundsNASDAQ:CMNDClearmind Medicine Inc
23/02/202412:06GlobeNewswire Inc.Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderNASDAQ:CMNDClearmind Medicine Inc
20/02/202412:14GlobeNewswire Inc.Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based CompoundsNASDAQ:CMNDClearmind Medicine Inc
20/02/202412:14GlobeNewswire Inc.SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based CompoundsNASDAQ:CMNDClearmind Medicine Inc
05/02/202412:51GlobeNewswire Inc.Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in ChinaNASDAQ:CMNDClearmind Medicine Inc
01/02/202413:15GlobeNewswire Inc.Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research CenterNASDAQ:CMNDClearmind Medicine Inc
16/01/202416:19GlobeNewswire Inc.Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private PlacementNASDAQ:CMNDClearmind Medicine Inc
11/01/202414:28GlobeNewswire Inc.Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private PlacementNASDAQ:CMNDClearmind Medicine Inc
10/01/202412:18GlobeNewswire Inc.Clearmind Medicine Completed Type A Meeting with the FDANASDAQ:CMNDClearmind Medicine Inc
04/01/202412:18GlobeNewswire Inc.Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based TreatmentsNASDAQ:CMNDClearmind Medicine Inc
04/01/202412:18GlobeNewswire Inc.SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based TreatmentsNASDAQ:CMNDClearmind Medicine Inc
14/12/202313:26GlobeNewswire Inc.Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing StandardsNASDAQ:CMNDClearmind Medicine Inc
05/12/202313:47GlobeNewswire Inc.Clearmind Medicine Achieved Positive Results in Cocaine Addiction TreatmentNASDAQ:CMNDClearmind Medicine Inc
01/12/202313:14GlobeNewswire Inc.Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical TrialNASDAQ:CMNDClearmind Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:CMND